Prajmaline: Difference between revisions

	WikiDoc Resources for Prajmaline
Articles
Most recent articles on Prajmaline Most cited articles on Prajmaline Review articles on Prajmaline Articles on Prajmaline in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Prajmaline Images of Prajmaline Photos of Prajmaline Podcasts & MP3s on Prajmaline Videos on Prajmaline
Evidence Based Medicine
Cochrane Collaboration on Prajmaline Bandolier on Prajmaline TRIP on Prajmaline
Clinical Trials
Ongoing Trials on Prajmaline at Clinical Trials.gov Trial results on Prajmaline Clinical Trials on Prajmaline at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Prajmaline NICE Guidance on Prajmaline NHS PRODIGY Guidance FDA on Prajmaline CDC on Prajmaline
Books
Books on Prajmaline
News
Prajmaline in the news Be alerted to news on Prajmaline News trends on Prajmaline
Commentary
Blogs on Prajmaline
Definitions
Definitions of Prajmaline
Patient Resources / Community
Patient resources on Prajmaline Discussion groups on Prajmaline Patient Handouts on Prajmaline Directions to Hospitals Treating Prajmaline Risk calculators and risk factors for Prajmaline
Healthcare Provider Resources
Symptoms of Prajmaline Causes & Risk Factors for Prajmaline Diagnostic studies for Prajmaline Treatment of Prajmaline
Continuing Medical Education (CME)
CME Programs on Prajmaline
International
Prajmaline en Espanol Prajmaline en Francais
Business
Prajmaline in the Marketplace Patents on Prajmaline
Experimental / Informatics
List of terms related to Prajmaline

Prajmaline
Clinical data
ATC code	C01BA08 (WHO) ;
Identifiers
	IUPAC name (4α,16R,17R,21α)-4-propylajmalan-4-ium-17,21-diol;
CAS Number	35080-11-6 ;
PubChem CID	37042;
ChemSpider	16735977 ;
UNII	75934UD4GJ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C23H33N2O2+
Molar mass	369.520 g/mol
3D model (JSmol)	Interactive image;
	SMILES O[C@@H]6C4[C@@H]2C[C@]65c1ccccc1N(C)[C@H]5[C@@H]3C[C@H]4[C@H](CC)[C@@H](O)[N+]23CCC;
	InChI InChI=1S/C23H33N2O2/c1-4-10-25-17-11-14(13(5-2)22(25)27)19-18(25)12-23(21(19)26)15-8-6-7-9-16(15)24(3)20(17)23/h6-9,13-14,17-22,26-27H,4-5,10-12H2,1-3H3/q+1/t13-,14-,17-,18-,19?,20-,21+,22+,23+,25?/m0/s1 ; Key:UAUHEPXILIZYCU-UUEXUKNBSA-N ;
(what is this?) (verify)

VisualWikitext

Latest revision as of 22:01, 23 July 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Prajmaline (Neo-gilurythmal)^[1] is a class Ia antiarrhythmic agent^[2] which has been available since the 1970s.^[3] Class Ia drugs increase the time one action potential lasts in the heart.^[4] Prajmaline is a semi-synthetic propyl derivative of ajmaline, with a higher bioavailability than its predecessor.^[5] It acts to stop arrhythmias of the heart through a frequency-dependent block of cardiac sodium channels.^[2]

Mechanism

Prajmaline causes a resting block in the heart.^[6] A resting block is the depression of a person's Vmax after a resting period. This effect is seen more in the atrium than the ventricle.^[6] The effects of some Class I antiarrhythmics are only seen in a patient who has a normal heart rate (~1 Hz).^[7] This is due to the effect of a phenomenon called reverse use dependence.^[7] The higher the heart rate, the less effect Prajmaline will have.

Uses

The drug Prajmaline has been used to treat a number of cardiac disorders. These include: coronary artery disease,^[8]^[9] angina,^[8]^[9] paroxysmal tachycardia and Wolff–Parkinson–White syndrome.^[1] Prajmaline has been indicated in the treatment of certain disorders where other antiarrhythmic drugs were not effective.^[1]

Administration

Prajmaline can be administered orally,^[9] parenterally^[8] or intravenously.^[8] Three days after the last dose, a limited effect has been observed. Therefore it has been suggested that treatment of arrhythmias with Prajmaline must be continuous to see acceptable results.^[1]

Pharmacokinetics

The main metabolites of Prajmaline are: 21-carboxyprajmaline and hydroxyprajmaline. Twenty percent of the drug is excreted in the urine unchanged.

Daily therapeutic dose is 40–80 mg. Distribution half-life is 10 minutes. Plasma protein binding is 60%. Oral bioavailability is 80%. Elimination half-life is 6 hours. Volume of distribution is 4-5 L/kg. ^[3]

Side Effects

There are no significant adverse side-effects of Prajmaline when taken alone and with a proper dosage.^[1]^[8]^[9] Patients who are taking other treatments for their symptoms (e.g. beta blockers and nifedipine) have developed minor transient conduction defects when given Prajmaline.^[8]

Overdose

An overdose of Prajmaline is possible. The range of symptoms seen during a Prajmaline overdose include: no symptoms, nausea/vomiting, bradycardia, tachycardia, hypotension, and death.^[3]

Other Potential Uses

Due to Prajmaline's sodium channel-blocking properties, it has been shown to protect rat white matter from anoxia (82 +/- 15%).^[10]^[11] The concentration used causes little suppression of the preanoxic response.^[10]^[11]

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 Janicki, K., J. Orski, and J. Kakol. "Antiarrhythmic Effects of Prajmaline (Neo-Gilurythmal) in Stable Angina Pectoris." Przegl Lek 52.10 (1995): 485-91. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/8834838>.
↑ ^2.0 ^2.1 Weirich, J., and H. Antoni. "Differential Analysis of the Frequency-Dependent Effects of Class 1 Antiarrhythmic Drugs According to Periodical Ligand Binding." Journal of Cardiovascular Pharmacology 15.6 (1990): 998-1009. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/1694924>.
↑ ^3.0 ^3.1 ^3.2 Koppel, Claus, Ursula Oberdisse, and Gerhard Heinemeyer. "Clinical Course and Outcome in Class IC Antiarrhythmic Overdose." Clinical Toxicology 28.4 (1990): 433-44. Web. 6 Feb. 2011. <http://informahealthcare.com/doi/pdf/10.3109/15563659009038586>.
↑ Milne, J. R., K. J. Hellestrand, R. S. Bexton, P. J. Burnett, N. Debbas, and A. Camm. "Class 1 Antiarrhythmic Drugs — Characteristic Electrocardiographic Differences When Assessed by Atrial and Ventricular Pacing." European Heart Journal 5 (1984): 99-107. Web. 6 Feb. 2011. <http://eurheartj.oxfordjournals.org/content/5/2/99.full.pdf>.
↑ Hinse, C., and J. Stöckigt. "The Structure of the Ring-opened N Beta-propyl-ajmaline (Neo-Gilurytmal) at Physiological PH Is Obviously Responsible for Its Better Absorption and Bioavailability When Compared with Ajmaline (Gilurytmal)." Pharmazie 55.7 (2000): 531-32. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/10944783>.
↑ ^6.0 ^6.1 Langenfeld, H., J. Weirich, C. Köhler, and K. Kochsiek. "Comparative Analysis of the Action of Class I Antiarrhythmic Drugs (Lidocaine, Quinidine, and Prajmaline) in Rabbit Atrial and Ventricular Myocardium." Journal of Cardiovascular Pharmacology 15.2 (1990): 338-45. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/1689432>.
↑ ^7.0 ^7.1 Langenfeld, H., C. Köhler, J. Weirich, M. Kirstein, and K. Kochsiek. "Reverse Use Dependence of Antiarrhythmic Class Ia, Ib, and Ic: Effects of Drugs on the Action Potential Duration?" Pacing and Clinical Electrophysiology 2nd ser. 15.11 (1992): 2097-102. Web. 6 Feb. 2011. <http://onlinelibrary.wiley.com/doi/10.1111/j.1540-8159.1992.tb03028.x/pdf>.
↑ ^8.0 ^8.1 ^8.2 ^8.3 ^8.4 ^8.5 Sowton, E., I. D. Sullivan, and J. C. P. Crick. "Acute Haemodynamic Effects of Ajmaline and Prajmaline in Patients with Coronary Heart Disease." European Journal of Clinical Pharmacology 26.2 (1984): 147-50. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/6723753>.
↑ ^9.0 ^9.1 ^9.2 ^9.3 Handler, C. E., A. Kritikos, I. D. Sullivan, A. Charalambakis, and E. Sowton. "Effects of Oral Prajmaline Bitartrate on Exercise Test Responses in Patients with Coronary Artery Disease." European Journal of Clinical Pharmacology 28.4 (1985): 371-74. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/4029242>.
↑ ^10.0 ^10.1 Stys, PK. "Protective Effects of Antiarrhythmic Agents against Anoxic Injury in CNS White Matter." Journal of Cerebral Blood Flow & Metabolism 15.3 (1995): 425-32. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/7714000>.
↑ ^11.0 ^11.1 Malek, S., J. Adorante, and P. Stys. "Differential Effects of Na-K-ATPase Pump Inhibition, Chemical Anoxia, and Glycolytic Blockade on Membrane Potential of Rat Optic Nerve." Brain Research 1037.1-2 (2005): 171-79.

Template:Antiarrhythmic agents

[Jan-1] 1.0 ^1.1 ^1.2 ^1.3 ^1.4 Janicki, K., J. Orski, and J. Kakol. "Antiarrhythmic Effects of Prajmaline (Neo-Gilurythmal) in Stable Angina Pectoris." Przegl Lek 52.10 (1995): 485-91. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/8834838>.

[Weir-2] 2.0 ^2.1 Weirich, J., and H. Antoni. "Differential Analysis of the Frequency-Dependent Effects of Class 1 Antiarrhythmic Drugs According to Periodical Ligand Binding." Journal of Cardiovascular Pharmacology 15.6 (1990): 998-1009. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/1694924>.

[Kopp-3] 3.0 ^3.1 ^3.2 Koppel, Claus, Ursula Oberdisse, and Gerhard Heinemeyer. "Clinical Course and Outcome in Class IC Antiarrhythmic Overdose." Clinical Toxicology 28.4 (1990): 433-44. Web. 6 Feb. 2011. <http://informahealthcare.com/doi/pdf/10.3109/15563659009038586>.

[4] Milne, J. R., K. J. Hellestrand, R. S. Bexton, P. J. Burnett, N. Debbas, and A. Camm. "Class 1 Antiarrhythmic Drugs — Characteristic Electrocardiographic Differences When Assessed by Atrial and Ventricular Pacing." European Heart Journal 5 (1984): 99-107. Web. 6 Feb. 2011. <http://eurheartj.oxfordjournals.org/content/5/2/99.full.pdf>.

[5] Hinse, C., and J. Stöckigt. "The Structure of the Ring-opened N Beta-propyl-ajmaline (Neo-Gilurytmal) at Physiological PH Is Obviously Responsible for Its Better Absorption and Bioavailability When Compared with Ajmaline (Gilurytmal)." Pharmazie 55.7 (2000): 531-32. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/10944783>.

[Lang-6] 6.0 ^6.1 Langenfeld, H., J. Weirich, C. Köhler, and K. Kochsiek. "Comparative Analysis of the Action of Class I Antiarrhythmic Drugs (Lidocaine, Quinidine, and Prajmaline) in Rabbit Atrial and Ventricular Myocardium." Journal of Cardiovascular Pharmacology 15.2 (1990): 338-45. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/1689432>.

[Langen-7] 7.0 ^7.1 Langenfeld, H., C. Köhler, J. Weirich, M. Kirstein, and K. Kochsiek. "Reverse Use Dependence of Antiarrhythmic Class Ia, Ib, and Ic: Effects of Drugs on the Action Potential Duration?" Pacing and Clinical Electrophysiology 2nd ser. 15.11 (1992): 2097-102. Web. 6 Feb. 2011. <http://onlinelibrary.wiley.com/doi/10.1111/j.1540-8159.1992.tb03028.x/pdf>.

[Sow-8] 8.0 ^8.1 ^8.2 ^8.3 ^8.4 ^8.5 Sowton, E., I. D. Sullivan, and J. C. P. Crick. "Acute Haemodynamic Effects of Ajmaline and Prajmaline in Patients with Coronary Heart Disease." European Journal of Clinical Pharmacology 26.2 (1984): 147-50. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/6723753>.

[Hand-9] 9.0 ^9.1 ^9.2 ^9.3 Handler, C. E., A. Kritikos, I. D. Sullivan, A. Charalambakis, and E. Sowton. "Effects of Oral Prajmaline Bitartrate on Exercise Test Responses in Patients with Coronary Artery Disease." European Journal of Clinical Pharmacology 28.4 (1985): 371-74. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/4029242>.

[Stys-10] 10.0 ^10.1 Stys, PK. "Protective Effects of Antiarrhythmic Agents against Anoxic Injury in CNS White Matter." Journal of Cerebral Blood Flow & Metabolism 15.3 (1995): 425-32. PubMed. Web. 6 Feb. 2011. <http://www.ncbi.nlm.nih.gov/pubmed/7714000>.

[Malek-11] 11.0 ^11.1 Malek, S., J. Adorante, and P. Stys. "Differential Effects of Na-K-ATPase Pump Inhibition, Chemical Anoxia, and Glycolytic Blockade on Membrane Potential of Rat Optic Nerve." Brain Research 1037.1-2 (2005): 171-79.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

@@ Line 3: / Line 3: @@
 | verifiedrevid = 464212942
 | IUPAC_name = (4α,16''R'',17''R'',21α)-4-propylajmalan-4-ium-17,21-diol
-| image = Prajmaline.svg
+| image = Prajmaline.png
 <!--Clinical data-->
@@ Line 84: / Line 84: @@
 ==References==
-{{Reflist}}
+{{reflist|2}}
 {{Antiarrhythmic agents}}
-[[Category:Alkaloids]]
+[[Category:Antiarrhythmic agents]]
-[[Category:Sodium channel blockers]]
+[[Category:Cardiovascular Drugs]]
-[[Category:Alcohols]]
+[[Category:Drug]]

Clinical data

ATC code	C01BA08 (WHO)
Identifiers
IUPAC name (4α,16R,17R,21α)-4-propylajmalan-4-ium-17,21-diol
CAS Number	35080-11-6^N
PubChem CID	37042
ChemSpider	16735977^Y
UNII	75934UD4GJ
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₃H₃₃N₂O₂⁺
Molar mass	369.520 g/mol
3D model (JSmol)	Interactive image
SMILES O[C@@H]6C4[C@@H]2C[C@]65c1ccccc1N(C)[C@H]5[C@@H]3C[C@H]4[C@H](CC)[C@@H](O)[N+]23CCC
InChI InChI=1S/C23H33N2O2/c1-4-10-25-17-11-14(13(5-2)22(25)27)19-18(25)12-23(21(19)26)15-8-6-7-9-16(15)24(3)20(17)23/h6-9,13-14,17-22,26-27H,4-5,10-12H2,1-3H3/q+1/t13-,14-,17-,18-,19?,20-,21+,22+,23+,25?/m0/s1^Y Key:UAUHEPXILIZYCU-UUEXUKNBSA-N^Y
^NY (what is this?) (verify)